Showing 1121-1130 of 1211 results for "".
- Johnson & Johnson Vision Donates $320K to Support Practitioners and Schools of Optometry Impacted by COVID-19https://modernod.com/news/johnson-johnson-vision-donates-320k-to-support-practitioners-and-schools-of-optometry-impacted-by-covid-19/2477924/As part of ongoing initiatives to help support eye care in the wake of COVID-19, Johnson & Johnson Vision announced donations to Optometry Cares, the charitable foundation of The American Optometric Association (AOA) Foundation and the American Academy of Optometry Foundation (AAOF). A
- Two ARVO Papers Provide New Insights for Contact Lens-Based Myopia Management with Childrenhttps://modernod.com/news/two-arvo-papers-provide-new-insights-for-contact-lens-based-myopia-management-with-children/2477900/Two scientific papers being presented as part of the ARVO (Association for Research in Vision and Ophthalmology) 2020 virtual conference proceedings provide eye care professionals (ECPs) with new insights to aid contact lens-based myopia management with children. ReCSS Study Ex
- Eversight Awarded Targeted Research Grant to Analyze COVID-19 Effects on Eye Donationhttps://modernod.com/news/eversight-awarded-targeted-research-grant-to-analyze-covid-19-effects-on-eye-donation/2477886/Eversight has been awarded an Eye Bank Association of America (EBAA) Targeted Research Grant to investigate COVID-19 testing of potential eye tissue donors and how COVID-19 infection affects the safety of eye tissues donated for sight-restoring transplants. Individuals known or suspected o
- Novartis Provides Update On Use and Safety of Beovu (brolucizumab)https://modernod.com/news/novartis-provides-update-on-use-and-safety-of-beovu-brolucizumab/2477873/An internal review of post-marketing safety case reports of brolucizumab (Beovu; Novartis) has confirmed a rare occurrence of intraocular inflammation (IOI) in association with retinal vasculitis and retinal vascular occlusion. Following FDA approval of Beovu in October 2019, Novartis rece
- ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through ARVOhttps://modernod.com/news/proqr-announces-virtual-presentation-of-phase-1-2-sepofarsen-data-through-arvo/2479525/ProQR Therapeutics announced a virtual presentation of data from the company’s phase 1/2 trial of sepofarsen. The data will be shared via a video presentation through the Association for Research in Vision and Ophthalmology (ARVO). It is the first time this data, previously announced in a
- ELT Sight’s ExTra Excimer Laser Trabeculostomy Procedure Receives New CPT Codeshttps://modernod.com/news/elt-sights-extra-excimer-laser-trabeculostomy-procedure-receives-new-cpt-codes/2477680/ELT Sight announced that the American Medical Association (AMA) approved two new Category III Current Procedural Terminology (CPT) codes to report ELT Sight’s ExTra Excimer Laser Trabeculostomy (ELT) procedure. The two new codes, to be used for reporting trabeculostomy ab interno by laser with or
- Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial of Dextenza for Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-announces-topline-results-of-phase-3-clinical-trial-of-dextenza-for-allergic-conjunctivitis/2477659/Ocular Therapeutix announced topline results from its phase 3 clinical trial to evaluate the safety and efficacy of Dextenza for the treatment of ocular itching associated with allergic conjunctivitis (AC). In the phase 3 trial, Dextenza met all prespecified primary endpoints as demonstrated by a
- Aldeyra Therapeutics Announces Potential of ADX-629 to Treat COVID-19 Patientshttps://modernod.com/news/aldeyra-therapeutics-announces-potential-of-adx-629-to-treat-covid-19-patients/2477578/Aldeyra Therapeutics, which has several drug candidates for the treatment of ocular inflammatory diseases, plans to facilitate the clinical testing of its drug candidate ADX-629 in patients with COVID-19-associated respiratory compromise. The company has requested a pre-investigational new drug m
- Optometry’s Meeting Cancelled Due to COVID-19https://modernod.com/news/optometrys-meeting-cancelled-due-to-covid-19/2477565/Out of an abundance of caution amid the ongoing COVID-19 pandemic, the American Optometric Association (AOA) has officially cancelled the annual Optometry’s Meeting, scheduled to take place on June 24-28 in Washington DC. The annual meeting of both the AOA and American Optometric Student As
- Alcon Provides Update on COVID-19https://modernod.com/news/alcon-provides-update-on-covid-19/2477538/Alcon announced a series of updates stemming from the impact of COVID-19. Alcon has initiated business continuity plans designed to keep its associates and customers safe while continuing to deliver critical eye care needs for the global healthcare community. These plans include directing